Patents by Inventor Stelios T. Tzannis

Stelios T. Tzannis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • mTORC modulators and uses thereof
    Patent number: 11702429
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: July 18, 2023
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • MTORC MODULATORS AND USES THEREOF
    Publication number: 20230080483
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 16, 2023
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • MTORC MODULATORS AND USES THEREOF
    Publication number: 20230013344
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Application
    Filed: May 21, 2021
    Publication date: January 19, 2023
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • mTORC modulators and uses thereof
    Patent number: 11230557
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: January 25, 2022
    Assignee: Aeovian Pharmaceuticals, Inc.
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • mTORC modulators and uses thereof
    Patent number: 11021492
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 1, 2021
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • MTORC MODULATORS AND USES THEREOF
    Publication number: 20210008041
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 14, 2021
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • MTORC MODULATORS AND USES THEREOF
    Publication number: 20210002300
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 7, 2021
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • Diffusional implantable delivery system
    Patent number: 5972369
    Abstract: A sustained release delivery system for delivering a beneficial agent is provided. The system includes a reservoir comprising the beneficial agent and a capillary channel in communication with the reservoir and the exterior of the system for delivering the beneficial agent from the system. The capillary channel has a cross-sectional area and a length selected to deliver the beneficial agent at a predetermined rate. The system may further include an outer surface that is impermeable and non-porous during delivery of the beneficial agent. The beneficial agent may be formulated in a glassy sugar matrix.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: October 26, 1999
    Assignee: ALZA Corporation
    Inventors: Wouter E. Roorda, Keith E. Dionne, James E. Brown, Jeremy C. Wright, Craig R. Davis, Steven J. Prestrelski, Stelios T. Tzannis